معرفی
Gabriella Gobbi, MD, PhD is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and Professor in the Department of Psychiatry within the Faculty of Medicine and Health Sciences at McGill University. She holds the prestigious Canada Research Chair (Tier 1) in Therapeutics for Mental Health, reflecting her significant contributions to the field of neuropsychopharmacology.
Dr. Gobbi's research program spans from bench to bedside, bridging fundamental neuroscience with clinical applications. Her laboratory investigates the pathophysiology of mental diseases and has made significant discoveries in developing novel treatments. Key areas of focus include:
- The effects of cannabis use in adolescence on later mental health outcomes
- Development of selective melatonin MT1 and MT2 receptor agonists for treating pain, insomnia, and anxiety
- Mechanisms of action of psychedelics (LSD, psilocybin) for treating anxiety disorders
- Endocannabinoid system modulation in mood disorders
- Sleep regulation through melatonin receptor pathways
Dr. Gobbi's extensive publication record demonstrates a clear trend toward investigating psychedelic compounds for mental health treatment. Her recent work has focused on elucidating the neural mechanisms by which LSD and psilocybin exert therapeutic effects in anxiety and depression, particularly examining their interactions with serotonin and dopamine systems. She has also made significant contributions to understanding how melatonin receptor subtypes selectively regulate different sleep stages and pain pathways.
Among her notable professional achievements is the Canada Research Chair (Tier 1) in Therapeutics for Mental Health, recognizing her leadership in developing novel pharmacological approaches for mental health disorders. Her research has led to multiple patents, including:
- Novel selective agonists of melatonin MT1 and MT2 receptors
- Patents related to the mechanism of action of LSD and psychedelics
Dr. Gobbi leads an active research program within the Brain Repair and Integrative Neuroscience (BRaIN) Program at RI-MUHC. Her laboratory employs a multidisciplinary approach combining behavioral pharmacology, electrophysiology, molecular biology, and clinical research to investigate novel therapeutics for mental health conditions. She collaborates extensively with researchers across McGill University and internationally, particularly in the emerging field of psychedelic medicine.
